发布求助
文献互助 智能选刊 最新文献

Cancer treatment reports最新文献

筛选
英文 中文
Semiautomated colorimetric assay for in vitro screening of anticancer compounds. 体外筛选抗癌化合物的半自动比色法。
Cancer treatment reports Pub Date : 1987-12-01
R L Ruben, R H Neubauer
{"title":"Semiautomated colorimetric assay for in vitro screening of anticancer compounds.","authors":"R L Ruben,&nbsp;R H Neubauer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An in vitro tetrazolium dye (MTT) reduction technique was modified and evaluated for use in the large-scale screening of anticancer compounds by examining the activity of ten clinically used drugs against 16 different human and murine cell populations. Cell populations included colon and mammary adenocarcinomas, melanomas, leukemias, and freshly isolated normal cells. Cell lines were grown in microtiter plates for 18-20 hours prior to a 72-hour continuous exposure to the drugs. Cultures were initiated at cell densities which maximized both the difference in dye reduction and the number of cell doublings between the beginning and end of the drug exposure period. Drug potency, expressed as the 50% inhibitory concentration (IC50), was comparable whether the effect on cell doublings or dye reduction was determined. There was good agreement between this method and the more labor-intensive, conventional method of counting trypan blue dye-excluding cells in a hemacytometer. Implemented as a large-scale, high-capacity system, our adaptation of the MTT technique is a rapid, sensitive, reproducible first-line screening device for detecting anticancer compounds with cytostatic or cytocidal activity.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1141-9"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14809708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase I trial of N-methylformamide in pediatric patients with refractory leukemias. n -甲基甲酰胺治疗难治性白血病患儿的I期临床试验。
Cancer treatment reports Pub Date : 1987-12-01
S B Murphy, J Mirro, C H Pui, C B Pratt
{"title":"Phase I trial of N-methylformamide in pediatric patients with refractory leukemias.","authors":"S B Murphy,&nbsp;J Mirro,&nbsp;C H Pui,&nbsp;C B Pratt","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1299-300"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14810302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: a Southwest Oncology Group Study. 螺锗治疗晚期前列腺腺癌的II期研究:西南肿瘤组研究。
Cancer treatment reports Pub Date : 1987-12-01
J H Saiers, B Blumenstein, M Slavik, J H Costanzi, E D Crawford
{"title":"Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: a Southwest Oncology Group Study.","authors":"J H Saiers,&nbsp;B Blumenstein,&nbsp;M Slavik,&nbsp;J H Costanzi,&nbsp;E D Crawford","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1305-6"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14810305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial. 转移性乳腺癌在环磷酰胺、阿霉素和5-氟尿嘧啶(CAF)诱导后的多重药物强化:一项东南癌症研究小组II期试验
Cancer treatment reports Pub Date : 1987-12-01
C L Vogel, M Raney, J Carpenter
{"title":"Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial.","authors":"C L Vogel,&nbsp;M Raney,&nbsp;J Carpenter","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1271-3"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14810444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study. 磷酸氟达拉滨在头颈癌患者中的II期试验:西南肿瘤组研究。
Cancer treatment reports Pub Date : 1987-12-01
G B Weiss, B Metch, D D Von Hoff, S A Taylor, J H Saiers
{"title":"Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study.","authors":"G B Weiss,&nbsp;B Metch,&nbsp;D D Von Hoff,&nbsp;S A Taylor,&nbsp;J H Saiers","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1313-4"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13593975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. 5-氟尿嘧啶联合亚叶酸临床研究现状及未来发展方向综述。
Cancer treatment reports Pub Date : 1987-12-01
J L Grem, D F Hoth, J M Hamilton, S A King, B Leyland-Jones
{"title":"Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid.","authors":"J L Grem,&nbsp;D F Hoth,&nbsp;J M Hamilton,&nbsp;S A King,&nbsp;B Leyland-Jones","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1249-64"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14445205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. 欧洲癌症研究和治疗组织(EORTC)低剂量周用表柔比星治疗转移性前列腺癌的II期研究。
Cancer treatment reports Pub Date : 1987-12-01
W G Jones, S D Fosså, A V Bono, J G Klijn, M De Pauw, R Sylvester
{"title":"European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer.","authors":"W G Jones,&nbsp;S D Fosså,&nbsp;A V Bono,&nbsp;J G Klijn,&nbsp;M De Pauw,&nbsp;R Sylvester","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1317-8"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14603917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cyclophosphamide hypersensitivity and cross-reactivity with chlorambucil. 环磷酰胺过敏及与氯霉素的交叉反应性。
Cancer treatment reports Pub Date : 1987-12-01
L Kritharides, K Lawrie, G A Varigos
{"title":"Cyclophosphamide hypersensitivity and cross-reactivity with chlorambucil.","authors":"L Kritharides,&nbsp;K Lawrie,&nbsp;G A Varigos","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1323-4"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14623003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer. 预治疗的晚期乳腺癌患者口服与静脉注射大剂量醋酸甲孕酮。
Cancer treatment reports Pub Date : 1987-12-01
L Beex, J Burghouts, J van Turnhout, W Breed, H Hillen, A Holdrinet, G Boetius, G Hoogendoorn, W Doesburg, M Verhulst
{"title":"Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.","authors":"L Beex,&nbsp;J Burghouts,&nbsp;J van Turnhout,&nbsp;W Breed,&nbsp;H Hillen,&nbsp;A Holdrinet,&nbsp;G Boetius,&nbsp;G Hoogendoorn,&nbsp;W Doesburg,&nbsp;M Verhulst","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In a multicenter trial, 123 patients with advanced breast cancer who had been treated with tamoxifen and/or chemotherapy were randomized to receive medroxyprogesterone acetate (MPA) orally 300 mg X 3 daily or im 500 mg daily for 4 weeks and 500 mg X 2 weekly thereafter. All case histories were reviewed extramurally by the criteria of the International Union Against Cancer. Five and 11 patients were not eligible and evaluable for response, respectively. Pretreatment characteristics were well balanced in both treated groups. Twenty-five of all 107 (23%) evaluable patients achieved an objective remission, whereas in a further 15% the disease became stable after previous progression. Results in both treatment arms did not differ significantly. The median duration of objective remission was 12 and 14 months for orally and im treated patients, respectively (P greater than 0.10). No statistically significant differences in the survival times of orally and im treated patients were found. Pretreatment characteristics positively correlated with an objective remission during MPA therapy in both groups were age greater than 50 years (P less than 0.02) and no previous chemotherapy (P less than 0.01). Toxicity included an increase in body weight, cushingoid effects, muscle cramps, and tremors in both groups. In four patients on im therapy, local infections developed. Mean serum MPA levels reached values above 100 ng/ml in nine orally and eight im treated patients (P greater than 0.10), and neither differed significantly in the patients responding to or failing therapy. In both MPA arms, plasma cortisol levels were suppressed. The drop in plasma cortisol levels was more pronounced in patients with objective remissions than in patients who failed (P = 0.04). In conclusion, oral and im MPA in the given doses had similar activity. Im administration of MPA should be reserved for patients not able to take oral medication.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1151-6"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14809709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study. 天尼泊苷在转移性肾癌和膀胱癌中的作用:一项西南肿瘤组研究。
Cancer treatment reports Pub Date : 1987-12-01
N Oishi, J Berenberg, B A Blumenstein, K Johnson, S E Rivkin, R M Bukowski, R M O'Bryan, R L Stephens, J Quagliana, J H Saiers
{"title":"Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.","authors":"N Oishi,&nbsp;J Berenberg,&nbsp;B A Blumenstein,&nbsp;K Johnson,&nbsp;S E Rivkin,&nbsp;R M Bukowski,&nbsp;R M O'Bryan,&nbsp;R L Stephens,&nbsp;J Quagliana,&nbsp;J H Saiers","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1307-8"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14810306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信